{
    "clinical_study": {
        "@rank": "82341", 
        "arm_group": [
            {
                "arm_group_label": "Standard of Care (SoC)", 
                "arm_group_type": "No Intervention", 
                "description": "Subjects randomized to the Standard of Care Arm will receive their HIV clinic's current standard of care retention services."
            }, 
            {
                "arm_group_label": "SoC + ALERT Intervention", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects randomized into the ALERT Enhanced Retention Intervention Arm will receive SoC at the HIV clinic where subjects are seen. In addition to SoC, the Intervention arm will receive aggressive engagement efforts by the ALERT specialist to ensure visit continuity and retention into care. The ALERT specialist will also administer an education intervention consisting of 5 retention modules designed to improve HIV knowledge and self-efficacy, and will also monitor health care visits and intervene via methods to track, find, and re-engage patients during the study."
            }
        ], 
        "brief_summary": {
            "textblock": "CCTG 594 is a controlled, unblinded, two-arm, randomized (1:1) clinical trial to evaluate\n      the effectiveness of a clinic-based HIV ALERT specialist on improving endpoints of retention\n      in care and maintenance of ART as compared to the current standard of care (SoC) in HIV\n      primary care clinics."
        }, 
        "brief_title": "CCTG 594: Engagement and Retention in Care for HIV+", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Patient Adherence", 
            "HIV Positive"
        ], 
        "condition_browse": {
            "mesh_term": "HIV Seropositivity"
        }, 
        "detailed_description": {
            "textblock": "Design: CCTG 594 is a controlled, unblinded, two-arm, randomized (1:1) clinical trial to\n      evaluate the effectiveness of a clinic-based HIV ALERT specialist on improving endpoints of\n      retention in care and maintenance of ART as compared to the current standard of care (SoC)\n      in HIV primary care clinics.\n\n      Duration: Each subject will receive follow-up of at least 48 weeks.\n\n      Sample Size: A total of 300 subjects will be randomized, 150 per arm.\n\n      Study Population: Eligible subjects will include 1) newly diagnosed HIV-infected individuals\n      entering primary HIV care at one of the CCTG clinics, or 2) previously diagnosed\n      HIV-infected individuals who are out of care (\"out of care\" defined using the gap measure (\n      no primary care visit in the last 180 days and not on a stable ART regimen).\n\n      Stratification: Subjects will be stratified based on primary HIV care clinic site and if\n      they are newly diagnosed or returning to care.  100 patients per study site, 50 in the\n      intervention arm, 50 in SoC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV-1 infection, as documented by any licensed screening antibody test, such as\n             ELISA, and confirmed by a second antibody test, such as Western blot, or detectable\n             plasma HIV-1 RNA at any time prior to study entry. If an ELISA or Western blot is not\n             available, HIV infection may be documented by two HIV RNA values \u22652000 copies/mL,\n             drawn at least 24 hours apart.  The RNA assays must have been run at a CLIA-approved\n             laboratory or equivalent.\n\n          -  18 years of age or older.\n\n          -  Able to give written informed consent.\n\n          -  New patient to the clinic (defined as having their intake visit within 90 days of\n             first testing positive for HIV) or a patient returning to care (defined as a patient\n             previously seen at least once by a prescribing HIV provider who has not seen a\n             prescribing HIV provider in the last 180 days and is not on a stable ARV regimen).\n\n          -  English or Spanish Speaking.\n\n          -  Registered to receive HIV primary care services at one of the identified\n             CCTG-affiliated clinic, i.e. the Owen Clinic at UC San Diego Health System,\n             Harbor-UCLA Medical Center clinic or Rand Schrader clinic at USC.\n\n        Exclusion Criteria:\n\n          -  Unstable neurologic, psychiatric, or physical condition which, in the opinion of the\n             investigator, would limit participation with study procedures for the duration of the\n             study.\n\n          -  A level of drug or alcohol use that, in the opinion of the investigator, would\n             preclude safe participation in the study.\n\n          -  Resident of nursing home or skilled facility.\n\n          -  Pregnant or breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957748", 
            "org_study_id": "CCTG 594"
        }, 
        "intervention": {
            "arm_group_label": "SoC + ALERT Intervention", 
            "description": "Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.", 
            "intervention_name": "SoC + ALERT Intervention", 
            "intervention_type": "Behavioral"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Retention", 
            "Care", 
            "Engagement"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90815"
                    }, 
                    "name": "City of Long Beach Department of Health and Human Services"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "dvillafu@usc.edu", 
                    "last_name": "Daisy Villafuerte", 
                    "phone": "323-343-8282"
                }, 
                "contact_backup": {
                    "email": "janissem@usc.edu", 
                    "last_name": "Janisse Mercado", 
                    "phone": "323.343.8282"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "University Southern California"
                }, 
                "investigator": {
                    "last_name": "Michael Dube, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "krwalsh@ucsd.edu", 
                    "last_name": "Kelly Walsh, MS", 
                    "phone": "619-543-8080"
                }, 
                "contact_backup": {
                    "email": "eseefried@ucsd.edu", 
                    "last_name": "Edward Seefried, RN", 
                    "phone": "619.543.8080"
                }, 
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "University of California, San Diego"
                }, 
                "investigator": {
                    "last_name": "Amy Sitapati, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vcorrea@labiomed.org", 
                    "last_name": "Vanessa Correa", 
                    "phone": "424-201-3000", 
                    "phone_ext": "7302"
                }, 
                "contact_backup": {
                    "email": "kcalvo@labiomed.org", 
                    "last_name": "Katya Calvo, MD", 
                    "phone": "310.222.3848"
                }, 
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90502"
                    }, 
                    "name": "Harbor-UCLA Medical Center"
                }, 
                "investigator": {
                    "last_name": "Eric Daar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "CCTG 594: Engagement and Retention in Care for HIV+, A Multicenter Trial of the California Collaborative Treatment Group", 
        "other_outcome": [
            {
                "description": "Descriptive secondary analyses comparing the two randomized groups will include:\nBaseline and follow-up scores on HIV and health literacy assessments, disclosure rates, adherence, and measures of self-efficacy\nNumber of primary care visits per year\nHIV RNA < 50 and <200 copies/mL at years 1 and 2\nCD4 cell counts and changes from baseline in CD4 at years 1 through 2\nScores on Beck Depression Index\nSubstance use\nHIV high-risk transmission behaviors\nTime to AIDS diagnosis or death", 
                "measure": "Descriptive analyses", 
                "safety_issue": "No", 
                "time_frame": "Baseline to two years"
            }, 
            {
                "description": "Proportions of subjects that meet the primary endpoint but subsequently return to care will be compared between the randomized groups. The times between last visit and return visit will also be compared between the randomized groups.", 
                "measure": "Return to Care after Primary Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 2 years"
            }
        ], 
        "overall_contact": {
            "email": "asitapati@ucsd.edu", 
            "last_name": "Amy Sitapati, MD", 
            "phone": "619-543-2535"
        }, 
        "overall_contact_backup": {
            "email": "eellorin@ucsd.edu", 
            "last_name": "Eric E Ellorin", 
            "phone": "619.543.5011"
        }, 
        "overall_official": [
            {
                "affiliation": "CCTG, UCSD AVRC, UCSD Owen Clinic", 
                "last_name": "Amy Sitapati, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "CCTG, UCSD AVRC", 
                "last_name": "Jeannette Aldous, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The CCTG 594 primary outcome is \"time to lost to follow up.\" Lost to follow up is defined as \"no visit with a prescribing HIV provider in the last 180 days. All randomized subjects will be followed for a minimum of 48 weeks. Subjects that do not meet the primary endpoint by the time the study ends will be censored.", 
            "measure": "Time to lost to follow up", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 48"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957748"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The CCTG 594 secondary outcome is \"time to initiation of ART.\" All randomized subjects will be followed for a minimum of 48 weeks. Subjects that do not initiate ART will be censored at their last visit date.", 
            "measure": "Time to initiation of ART", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 48"
        }, 
        "source": "California Collaborative Treatment Group", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of California, San Diego", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of California, Los Angeles", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Southern California", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "City of Long Beach Department of Health and Human Services", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "California HIV/AIDS Research Program", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "California Collaborative Treatment Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}